DK2970423T3 - Interleukin-2 muteiner for udvidelsen af t-regulatoriske celler - Google Patents

Interleukin-2 muteiner for udvidelsen af t-regulatoriske celler Download PDF

Info

Publication number
DK2970423T3
DK2970423T3 DK14722463.8T DK14722463T DK2970423T3 DK 2970423 T3 DK2970423 T3 DK 2970423T3 DK 14722463 T DK14722463 T DK 14722463T DK 2970423 T3 DK2970423 T3 DK 2970423T3
Authority
DK
Denmark
Prior art keywords
muteines
interleukin
extension
regulatory cells
regulatory
Prior art date
Application number
DK14722463.8T
Other languages
English (en)
Inventor
Marc A Gavin
Gunasekaran Kannan
Li Li
Joshua T Pearson
Margaret Karow
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK2970423T3 publication Critical patent/DK2970423T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
DK14722463.8T 2013-03-14 2014-03-14 Interleukin-2 muteiner for udvidelsen af t-regulatoriske celler DK2970423T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784669P 2013-03-14 2013-03-14
PCT/US2014/029111 WO2014153111A2 (en) 2013-03-14 2014-03-14 Interleukin-2 muteins for the expansion of t-regulatory cells

Publications (1)

Publication Number Publication Date
DK2970423T3 true DK2970423T3 (da) 2019-07-08

Family

ID=50680166

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14769541.5T DK2970441T3 (da) 2013-03-14 2014-03-14 AGLYCOSYLEREDE Fc-INDEHOLDENDE POLYPEPTIDER
DK14722463.8T DK2970423T3 (da) 2013-03-14 2014-03-14 Interleukin-2 muteiner for udvidelsen af t-regulatoriske celler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK14769541.5T DK2970441T3 (da) 2013-03-14 2014-03-14 AGLYCOSYLEREDE Fc-INDEHOLDENDE POLYPEPTIDER

Country Status (40)

Country Link
US (7) US9546203B2 (da)
EP (2) EP2970441B1 (da)
JP (5) JP6450365B2 (da)
KR (4) KR102219124B1 (da)
CN (2) CN105143253B (da)
AP (1) AP2015008737A0 (da)
AR (1) AR095541A1 (da)
AU (2) AU2014236316B2 (da)
BR (1) BR112015022440B1 (da)
CA (3) CA3149348C (da)
CL (2) CL2015002686A1 (da)
CR (2) CR20200004A (da)
CY (2) CY1121767T1 (da)
DK (2) DK2970441T3 (da)
EA (2) EA034326B1 (da)
ES (2) ES2737598T3 (da)
HK (1) HK1220695A1 (da)
HR (2) HRP20190970T1 (da)
HU (2) HUE044321T2 (da)
IL (2) IL241349B (da)
JO (1) JO3796B1 (da)
LT (2) LT2970441T (da)
MA (2) MA38477B1 (da)
ME (2) ME03482B (da)
MX (2) MX366854B (da)
MY (1) MY172991A (da)
NZ (1) NZ751148A (da)
PE (1) PE20151763A1 (da)
PH (1) PH12015502051B1 (da)
PL (2) PL2970423T3 (da)
PT (2) PT2970423T (da)
RS (2) RS58854B1 (da)
SG (2) SG11201507574VA (da)
SI (2) SI2970441T1 (da)
TN (1) TN2015000416A1 (da)
TR (2) TR201910802T4 (da)
TW (3) TWI687435B (da)
UA (1) UA119140C2 (da)
UY (1) UY35454A (da)
WO (2) WO2014153111A2 (da)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20190202898A9 (en) * 2012-04-03 2019-07-04 Novelmed Therapeutics, Inc. AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
CN104870474B (zh) * 2012-10-04 2019-03-12 诺沃姆德治疗公司 用于治疗溶血性疾病的旁路途径特异性抗体
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
AP2015008732A0 (en) 2013-03-15 2015-09-30 Amgen Inc Human pac1 antibodies
SI2970422T1 (en) 2013-03-15 2018-07-31 F. Hoffmann-La Roche Ag IL-22 polypeptides and IL-22-Fc fusion proteins and procedures for use
AU2015215001B2 (en) 2014-02-06 2019-08-15 F. Hoffmann-La Roche Ag Interleukin-2 fusion proteins and uses thereof
SG11201700514SA (en) * 2014-07-21 2017-02-27 Delinia Inc Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
PL3482766T3 (pl) 2014-08-11 2020-11-16 Delinia, Inc. Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych
TW201620938A (zh) 2014-09-15 2016-06-16 安美基公司 雙特異性抗cgrp受體/pac1受體抗原結合蛋白質及其用途
EP3233192B1 (en) * 2014-12-15 2021-04-14 Washington University Compositions and methods for targeted cytokine delivery
CA2982362A1 (en) * 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
MX2017012966A (es) 2015-04-10 2018-06-06 Amgen Inc Muteinas de interleuquina 2 para la expansion de celulas t regulatorias.
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
MA43567A (fr) 2015-12-15 2018-11-14 Amgen Inc Anticorps pacap et leurs utilisations
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
MD3411402T2 (ro) * 2016-02-03 2022-05-31 Amgen Res Munich Gmbh Constructe de anticorpi bispecifici BCMA și CD3 de angajare a celulei T
EA039859B1 (ru) * 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
FI3411404T3 (fi) * 2016-02-03 2023-01-31 T-soluja aktivoivia psma- ja cd3-bispesifisisiä vasta-ainekonstrukteja
JP7220458B2 (ja) 2016-02-05 2023-02-10 ワシントン・ユニバーシティ 標的サイトカインデリバリーのための組成物および方法
CN107287273B (zh) * 2016-03-31 2021-03-09 复旦大学附属妇产科医院 表达Tim-3的外周血NK细胞在制备自然流产生物标记物中的用途
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
JP7422480B2 (ja) * 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
WO2017220704A1 (en) 2016-06-22 2017-12-28 David Klatzmann Genetically modified t lymphocytes
WO2018027025A1 (en) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
KR101928981B1 (ko) * 2016-09-02 2018-12-13 고려대학교 산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
CA3041334A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
EP3551749B1 (en) 2016-12-07 2023-09-27 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells
CN110520436A (zh) 2017-03-15 2019-11-29 潘迪恩治疗公司 靶向免疫耐受性
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
US20200317795A1 (en) 2017-10-04 2020-10-08 Amgen Inc. Transthyretin immunoglobulin fusions
JP2021505156A (ja) * 2017-12-06 2021-02-18 パンディオン・オペレーションズ・インコーポレイテッド 標的化免疫寛容
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
SG11202003965VA (en) * 2017-12-06 2020-06-29 Pandion Therapeutics Inc Il-2 muteins and uses thereof
MX2020006322A (es) * 2017-12-19 2020-09-18 Xencor Inc Proteinas de fusion il-2 fc modificadas.
US20210060169A1 (en) * 2017-12-27 2021-03-04 Kyowa Kirin Co., Ltd. Il-2 variant
AR114080A1 (es) 2018-01-12 2020-07-22 Amgen Inc Anticuerpos pac1 y sus usos
US11534479B2 (en) 2018-02-16 2022-12-27 Iltoo Pharma Use of interleukin 2 for treating Sjögren's syndrome
TW202003551A (zh) * 2018-03-28 2020-01-16 美商必治妥美雅史谷比公司 介白素-2/介白素-2受體阿法融合蛋白及其使用方法
AU2019283621B2 (en) 2018-06-07 2023-03-30 Korea Research Institute Of Bioscience And Biotechnology Transgenic mouse for aglycosylated antibody production and use of aglycosylated antibody produced therefrom
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2019246392A1 (en) 2018-06-22 2019-12-26 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
MA53094A (fr) 2018-07-02 2021-05-12 Amgen Inc Protéine de liaison à l'antigène anti-steap1
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
EP3836954A1 (en) 2018-08-13 2021-06-23 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
KR20210087472A (ko) * 2018-11-01 2021-07-12 산동 뉴 타임 파마슈티칼 코., 리미티드. 이중 특이성 항체 및 그 용도
US20220088145A1 (en) 2019-02-08 2022-03-24 The Uab Research Foundation Immunotherapy for the treatment and prevention of inflammatory bowel disease
EP3924379A4 (en) 2019-02-15 2022-12-21 Integral Molecular, Inc. COMMON LIGHT CHAIN ANTIBODIES AND THEIR USES
AU2020223293A1 (en) 2019-02-15 2021-08-19 Integral Molecular, Inc. Claudin 6 antibodies and uses thereof
CA3134439A1 (en) 2019-03-29 2020-10-08 Institut Curie Interleukin-2 variants with modified biological activity
CN111944036A (zh) * 2019-05-14 2020-11-17 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
CN114269784A (zh) 2019-06-07 2022-04-01 美国安进公司 具有选择性可切割接头的双特异性结合构建体
WO2021007150A1 (en) 2019-07-08 2021-01-14 Amgen Inc. Multispecific transthyretin immunoglobulin fusions
AU2020323893A1 (en) * 2019-07-26 2022-02-17 Visterra, Inc. Interleukin-2 agents and uses thereof
AU2020328038A1 (en) * 2019-08-13 2022-03-31 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US20220340642A1 (en) 2019-09-13 2022-10-27 Kyowa Kirin Co., Ltd. Dcr3 variant
CA3157613A1 (en) * 2019-11-20 2021-05-27 Gi Cell, Inc. Medium composition for culturing t cells and method for culturing t cells using same
EP4048296A4 (en) * 2019-11-29 2024-01-24 Nkmax Co Ltd METHOD FOR PRODUCING NATURAL KILLER CELLS AND COMPOSITIONS THEREOF
JP2023505590A (ja) 2019-12-12 2023-02-09 イルトゥー・ファルマ インターロイキン２キメラ構築物
EP4077383A1 (en) 2019-12-17 2022-10-26 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
AU2020407233A1 (en) 2019-12-20 2022-08-18 Regeneron Pharmaceuticals, Inc. Novel IL2 agonists and methods of use thereof
IL294659A (en) 2020-01-14 2022-09-01 Synthekine Inc Methods and preparations of il2 skewed mutants
AU2021252514A1 (en) * 2020-04-06 2022-11-10 Lung Biotechnology Pbc Modular synthetic receptors and methods of use
AU2021273009A1 (en) 2020-05-13 2022-12-15 Bonum Therapeutics, Inc. Compositions of protein complexes and methods of use thereof
US20230203198A1 (en) 2020-06-04 2023-06-29 Amgen Inc. Bispecific binding constructs
WO2021253360A1 (en) * 2020-06-18 2021-12-23 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines
CN112048018B (zh) * 2020-08-31 2021-10-08 南方医科大学 一种嵌合t细胞生长因子及其应用
WO2022094275A1 (en) 2020-10-29 2022-05-05 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
CA3203468A1 (en) 2020-12-03 2022-06-09 Amgen Inc. Immunoglobuline constructs with multiple binding domains
US20220177535A1 (en) * 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
CA3216005A1 (en) 2021-05-27 2022-12-01 Jochen Beninga Fc variant with enhanced affinity to fc receptors and improved thermal stability
AU2022324624A1 (en) * 2021-08-06 2024-02-08 Amgen Inc. Isolation of therapeutic protein
CA3233644A1 (en) 2021-10-06 2023-04-13 David Klatzmann Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
WO2023061005A1 (zh) * 2021-10-14 2023-04-20 徕特康(苏州)生物制药有限公司 新型抗体-细胞因子融合蛋白及其制备方法和用途
US20230192843A1 (en) 2021-10-14 2023-06-22 Teneobio, Inc. Mesothelin binding proteins and uses thereof
US20240041981A1 (en) * 2021-12-01 2024-02-08 Visterra, Inc. Methods of using interleukin-2 agents
WO2023148397A1 (en) 2022-02-07 2023-08-10 Vib Vzw Engineered stabilizing aglycosylated fc-regions
WO2023164476A2 (en) * 2022-02-22 2023-08-31 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disorders
WO2023180527A1 (en) 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
WO2024026358A1 (en) 2022-07-27 2024-02-01 Teneobio, Inc. Mesothelin binding proteins and uses thereof
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233A (en) 1837-06-14 Improvement in plows
US4447A (en) 1846-04-04 Car- wheel
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0351410A1 (en) 1987-03-18 1990-01-24 3i RESEARCH EXPLOITATION LIMITED Complement-binding peptide
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
CA2062582C (en) 1991-03-27 1996-03-26 Tse-Wen Chang Methods and substances for recruiting therapeutic agents to solid tissues
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6037525A (en) 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
FR2752462B1 (fr) 1996-08-14 1998-10-23 Essilor Int Procede d'incorporation d'additifs dans un article ophtalmique au moyen d'un fluide a l'etat supercritique
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6177612B1 (en) 1998-07-31 2001-01-23 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada Matrix attachment regions
WO2000018938A1 (en) 1998-09-29 2000-04-06 Pioneer Hi-Bred International, Inc. Mar/sar elements flanking rsyn7-driven construct
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
EA005584B1 (ru) * 2000-12-07 2005-04-28 Эли Лилли Энд Компани Слитые белки glp-1
WO2002048379A1 (en) 2000-12-15 2002-06-20 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region fo interferon beta
CA2435972C (en) 2001-01-26 2011-09-13 University Of Lausanne Matrix attachment regions and methods for use thereof
US7186804B2 (en) 2001-12-04 2007-03-06 Emd Lexigen Research Center Corp. IL-2 fusion proteins with modulated selectivity
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CA2528591C (en) 2003-06-12 2013-01-08 Eli Lilly And Company Glp-1 analog fusion proteins
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
CN1938428A (zh) 2003-11-12 2007-03-28 先灵公司 多基因表达的质粒系统
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
RU2006135112A (ru) 2004-03-05 2008-04-10 Чирон Корпорейшн (Us) Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам
US7521541B2 (en) * 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
ES2605380T3 (es) * 2005-05-06 2017-03-14 Providence Health & Services - Oregon Proteina de fusión OX40-inmunoglobulina trimérica y métodos de uso
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
BRPI0612814A2 (pt) * 2005-07-11 2017-06-20 Macrogenics Inc anticorpo, métodos para redução e para tratamento de uma resposta imune prejudicial em um mamífero, proteína de ligação ao cd16a, e, método para redução dos efeitos colaterais de primeira dose em um paciente
WO2008112325A2 (en) 2007-03-15 2008-09-18 Biogen Idec Ma Inc. Treatment of autoimmune disorders
GB0623539D0 (en) 2006-11-24 2007-01-03 Avidex Ltd Polypeptides
US20090016935A1 (en) 2007-07-09 2009-01-15 Andrianov Alexander K Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
US8592562B2 (en) 2008-01-07 2013-11-26 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
AU2010206840B2 (en) 2009-01-21 2015-02-05 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
JP2012515556A (ja) * 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
MX340971B (es) 2009-11-23 2016-08-02 Amgen Inc * Fragmento cristalizable (fc) de anticuerpo monomerico.
KR20120107122A (ko) * 2009-12-22 2012-09-28 노파르티스 아게 치료법에서 사용하기 위한 ４가 ｃｄ４７―항체 불변 영역 융합 단백질
CN110251668A (zh) 2010-11-30 2019-09-20 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
TWI666027B (zh) * 2011-02-10 2019-07-21 羅齊克雷雅公司 突變介白素-２多肽
WO2012125850A1 (en) 2011-03-16 2012-09-20 Amgen Inc. Fc variants
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP3539982A3 (en) 2011-12-23 2020-01-15 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
CA2861122A1 (en) 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors
BR112014028838A2 (pt) 2012-05-21 2020-05-12 Genentech Inc Usos de um anticorpo, método para fazer um anticorpo e anticorpos
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
SI2970422T1 (en) * 2013-03-15 2018-07-31 F. Hoffmann-La Roche Ag IL-22 polypeptides and IL-22-Fc fusion proteins and procedures for use
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
PL2970423T3 (pl) 2019-10-31
LT2970441T (lt) 2019-06-10
US20180319859A1 (en) 2018-11-08
WO2014153111A2 (en) 2014-09-25
AU2014236281A1 (en) 2015-09-24
US10093711B2 (en) 2018-10-09
MA49207A1 (fr) 2021-09-30
PH12015502051A1 (en) 2016-01-18
ME03437B (me) 2020-01-20
US9546203B2 (en) 2017-01-17
US20140343252A1 (en) 2014-11-20
HRP20191075T1 (hr) 2019-09-20
TR201908362T4 (tr) 2019-06-21
US9580486B2 (en) 2017-02-28
PT2970423T (pt) 2019-07-23
JP6450365B2 (ja) 2019-01-09
LT2970423T (lt) 2019-05-27
CN105143253B (zh) 2021-02-19
TW202005979A (zh) 2020-02-01
CY1121767T1 (el) 2020-07-31
KR20230157526A (ko) 2023-11-16
TW201522366A (zh) 2015-06-16
KR20150130342A (ko) 2015-11-23
US20210094997A1 (en) 2021-04-01
IL241349B (en) 2018-08-30
EP2970441A4 (en) 2016-11-23
CA2906708A1 (en) 2014-09-25
SG11201507420UA (en) 2015-10-29
HUE043488T2 (hu) 2019-08-28
IL241349A0 (en) 2015-11-30
NZ712066A (en) 2021-05-28
TWI784288B (zh) 2022-11-21
US10562950B2 (en) 2020-02-18
RS58854B1 (sr) 2019-07-31
PH12015502051B1 (en) 2016-01-18
US20170137485A1 (en) 2017-05-18
KR20220101009A (ko) 2022-07-18
RS58791B1 (sr) 2019-07-31
CL2015002669A1 (es) 2016-09-09
EP2970423A2 (en) 2016-01-20
TWI687435B (zh) 2020-03-11
WO2014153063A1 (en) 2014-09-25
ES2720225T3 (es) 2019-07-18
TR201910802T4 (tr) 2019-08-21
MX366854B (es) 2019-07-26
CA3149348C (en) 2023-09-12
MX2015012912A (es) 2015-12-03
MA49207B1 (fr) 2022-08-31
US20180237489A1 (en) 2018-08-23
NZ751148A (en) 2021-05-28
BR112015023145A2 (pt) 2017-11-21
HRP20190970T1 (hr) 2019-07-26
US20170081382A1 (en) 2017-03-23
MX2015012890A (es) 2015-12-03
CA2905141A1 (en) 2014-09-25
JP2021040630A (ja) 2021-03-18
IL241622B (en) 2020-09-30
US10829535B2 (en) 2020-11-10
CA3149348A1 (en) 2014-09-25
JP2023053148A (ja) 2023-04-12
CR20150557A (es) 2015-11-10
EP2970441A1 (en) 2016-01-20
UA119140C2 (uk) 2019-05-10
AU2014236316B2 (en) 2018-11-01
CA2906708C (en) 2022-05-03
DK2970441T3 (da) 2019-06-03
HK1220695A1 (zh) 2017-05-12
CR20200004A (es) 2020-03-11
BR112015022440A2 (pt) 2017-10-24
AR095541A1 (es) 2015-10-21
MA38477A1 (fr) 2017-09-29
TWI709572B (zh) 2020-11-11
MY172991A (en) 2019-12-17
TN2015000416A1 (en) 2017-01-03
EA201591731A1 (ru) 2016-04-29
AU2014236316A1 (en) 2015-10-08
ME03482B (me) 2020-01-20
PL2970441T3 (pl) 2019-09-30
SI2970423T1 (sl) 2019-08-30
JP7227951B2 (ja) 2023-02-22
KR20150127185A (ko) 2015-11-16
EP2970423B1 (en) 2019-04-24
TW202115106A (zh) 2021-04-16
PT2970441T (pt) 2019-06-11
UY35454A (es) 2014-09-30
SG11201507574VA (en) 2015-10-29
JP2016518823A (ja) 2016-06-30
SI2970441T1 (sl) 2019-07-31
WO2014153111A3 (en) 2014-11-13
CN105143253A (zh) 2015-12-09
CY1121823T1 (el) 2020-07-31
EP2970441B1 (en) 2019-03-06
MA38477B1 (fr) 2019-05-31
AU2014236281B2 (en) 2018-03-08
JP2019058182A (ja) 2019-04-18
KR102219124B1 (ko) 2021-02-22
CN105358570A (zh) 2016-02-24
CN105358570B (zh) 2019-11-12
KR102418771B1 (ko) 2022-07-08
AP2015008737A0 (en) 2015-09-30
EA201591766A1 (ru) 2016-02-29
US9932380B2 (en) 2018-04-03
JP6480409B2 (ja) 2019-03-13
ES2737598T3 (es) 2020-01-15
US20140286898A1 (en) 2014-09-25
PE20151763A1 (es) 2015-12-10
EA032863B1 (ru) 2019-07-31
JO3796B1 (ar) 2021-01-31
CL2015002686A1 (es) 2016-04-15
EA034326B1 (ru) 2020-01-28
BR112015022440B1 (pt) 2022-08-16
AU2014236316A9 (en) 2018-11-08
HUE044321T2 (hu) 2019-10-28
JP2016514161A (ja) 2016-05-19

Similar Documents

Publication Publication Date Title
DK2970423T3 (da) Interleukin-2 muteiner for udvidelsen af t-regulatoriske celler
DK2981607T3 (da) Effektiv generering af tumormålrettede t-celler afledt af pluripotente stamceller
DK3395814T3 (da) Hæmmere af fibroblastvækstfaktorreceptoren
DK2970954T3 (da) Modifikation af polypeptider
DK3083540T3 (da) Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner
DK3239134T3 (da) Pyridonamider som modulatorer af natriumkanaler
DK3071223T3 (da) Cell
DK2845905T3 (da) Fremstilling af oligosaccharider
DK3006568T3 (da) Fremgangsmåde til fremstilling af tagatose
DK2931551T3 (da) Styring af rækkeviddeudvider
DK3027618T3 (da) Polymorf af syk-hæmmere
DK3087183T3 (da) Modulation af angiopoietin-3-lignende ekspression
DK2941483T3 (da) Fremgangsmåde til at opnå immunstimulerende dendritriske celler
DK3079658T3 (da) Kammer til indkapsling af secernerende celler
DK3013964T3 (da) Sammensætninger til indføring af rna i celler
DK3008039T3 (da) Krystallinsk form af en mdm2-inhibitor
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK3010352T3 (da) Fremgangsmåde til fremstilling af fodertilsætning
DK3068359T3 (da) Indikator for hældningen af sengen
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK3080304T3 (da) Fremgangsmåde til fremstillingen af sukre fra biomasse
DK3054782T3 (da) Fremgangsmåde til tørring af biomasse
DK2822568T3 (da) Anvendelser af caseinsammensætninger
DK2965026T3 (da) Generering af slushice
DK3071670T3 (da) Integreret fremgangsmåde til fremstilling af carbonhydrider